Two-step sandwich enzyme immunoassay using monoclonal antibodies for detection of soluble and membrane-associated human membrane type 1-matrix metalloproteinase

被引:12
作者
Aoki, T
Yonezawa, K
Ohuchi, E
Fujimoto, N
Iwata, K
Shimada, T
Shiomi, T
Okada, Y
Seiki, M
机构
[1] Fuji Chem Ind Co Ltd, Dept Biopharmaceut, Toyama 9338511, Japan
[2] Kyoto Prefectural Univ Med, Sch Med, Dept Otolaryngol, Kyoto, Japan
[3] Keio Univ, Sch Med, Dept Pathol, Keio, Japan
[4] Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Tokyo, Japan
关键词
D O I
10.1081/IAS-120002274
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A two-step sandwich enzyme immunoassay (EIA) system for the detection of human membrane Type 1-matrix metalloproteinase (MT1-MMP) was established by using two monoclonal antibodies against recombinant MT1-MMP. MT1-MMP in which samples were reacted with solid-phase antibody and then detected with peroxidase-labeled second antibody. At least 1.25 ng/mL was detected by the EIA system, and linearity was obtained between 1.25 and 160 ng/mL. This EIA system is specific for MT1-MMP and did not show cross-reactivity against several other MMP's examined. Shedding of soluble MT1-MMP into the medium by some cancer cell lines was also detected by this system. However, soluble MT1-MMP in serum from normal and cancer patients was under the detection limit. Membrane-associated MT1-MMP of cancer cell lines was also detected after solubilization of the membranes with extraction buffer containing detergent. Additionally, MT1-MMP in clinical samples was examined. Elevated levels of MT1-MMP were detected in homogenate of cancer tissue compared with the levels for normal tissue and the level of MT1-MMP in tumors correlated with the rate of metastasis to the regional lymph nodes. Thus, we demonstrated that this EIA system is the first to measure MT1-MMP in clinical specimens, thus suggesting its useful for diagnosis of cancer or prediction of malignancy.
引用
收藏
页码:49 / 68
页数:20
相关论文
共 35 条
[1]   THE C-TERMINAL REGION OF MEMBRANE TYPE MATRIX METALLOPROTEINASE IS A FUNCTIONAL TRANSMEMBRANE DOMAIN REQUIRED FOR PRO-GELATINASE-C ACTIVATION [J].
CAO, J ;
SATO, H ;
TAKINO, T ;
SEIKI, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (02) :801-805
[2]   Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases [J].
d'Ortho, MP ;
Will, H ;
Atkinson, S ;
Butler, G ;
Messent, A ;
Gavrilovic, J ;
Smith, B ;
Timpl, R ;
Zardi, L ;
Murphy, G .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 250 (03) :751-757
[3]   A ONE-STEP SANDWICH ENZYME-IMMUNOASSAY FOR HUMAN MATRIX METALLOPROTEINASE 2 (72-KDA GELATINASE TYPE-IV COLLAGENASE) USING MONOCLONAL-ANTIBODIES [J].
FUJIMOTO, N ;
MOURI, N ;
IWATA, K ;
OHUCHI, E ;
OKADA, Y ;
HAYAKAWA, T .
CLINICA CHIMICA ACTA, 1993, 221 (1-2) :91-103
[4]   Shedding of membrane type 1 matrix metalloproteinase in a human breast carcinoma cell line [J].
Harayama, T ;
Ohuchi, E ;
Aoki, T ;
Sato, H ;
Seiki, M ;
Okada, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09) :942-950
[5]  
Imai K, 1996, CANCER RES, V56, P2707
[6]   ENZYME-LABELING OF ANTIBODIES AND THEIR FRAGMENTS FOR ENZYME-IMMUNOASSAY AND IMMUNOHISTOCHEMICAL STAINING [J].
ISHIKAWA, E ;
IMAGAWA, M ;
HASHIDA, S ;
YOSHITAKE, S ;
HAMAGUCHI, Y ;
UENO, T .
JOURNAL OF IMMUNOASSAY, 1983, 4 (03) :209-327
[7]   Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase [J].
Itoh, Y ;
Kajita, M ;
Kinoh, H ;
Mori, H ;
Okada, A ;
Seiki, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (48) :34260-34266
[8]   Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface [J].
Lehti, K ;
Lohi, J ;
Valtanen, H ;
Keski-Oja, J .
BIOCHEMICAL JOURNAL, 1998, 334 :345-353
[9]  
Llano E, 1999, CANCER RES, V59, P2570
[10]   A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil collagenase) using monoclonal antibodies [J].
Matsuki, H ;
Fujimoto, N ;
Iwata, K ;
Knauper, V ;
Okada, Y ;
Hayakawa, T .
CLINICA CHIMICA ACTA, 1996, 244 (02) :129-143